Somatorelin

Summary

Somatorelin (also called Geref, GRF 1‑44, or somatocrinin) is a synthetic analogue of human growth‑hormone‑releasing hormone. It was once marketed as a prescription drug but has been withdrawn and is now used mainly in research, diagnostic testing, and anti‑doping laboratories. The peptide is administered by injection (intravenous or subcutaneous) to provoke a rapid release of growth hormone from the pituitary.

Mechanism of Action

Somatorelin mimics the natural 44‑amino‑acid GHRH peptide and binds to the GHRH receptor on anterior‑pituitary somatotroph cells. Receptor activation stimulates adenylate cyclase, raises cAMP, and triggers exocytosis of stored growth hormone. In some pituitary adenoma cultures the peptide also promoted release of thyroid‑stimulating hormone and prolactin, indicating broader pituitary effects under certain pathological conditions.

What the Research Shows

Clinical investigations have used somatorelin as a standardized GH‑releasing challenge. In a 2001 study it was given alongside apomorphine to differentiate Parkinson disease from multiple system atrophy, but no group differences in GH release were observed. Chemical synthesis advances in 2018 enabled rapid flow‑based production of the peptide for diagnostic use. A 2020 biomarker study showed that somatorelin administration produced consistent rises in IGF‑I and GH‑2000 scores in men, facilitating detection of GH‑stimulating doping, while variability was higher in women. An N‑of‑1 gene‑therapy report (2021) described sustained elevated circulating GHRH levels for over five years after intramuscular plasmid delivery, accompanied by metabolic changes such as improved lipid ratios and modest blood‑pressure reductions, though only a single subject was studied. In vitro work with a plurihormonal pituitary adenoma demonstrated that somatorelin could stimulate release of GH, TSH, and prolactin, whereas somatostatin uniformly inhibited secretion. Finally, a 2023 analytical method validated detection of somatorelin in urine at sub‑nanogram levels for anti‑doping testing.

Reported Benefits

Somatorelin provides a reliable, short‑acting stimulus of endogenous growth hormone, making it useful as a diagnostic probe in endocrine research and as a reference standard for assay development. Its synthetic availability enables precise dosing in experimental protocols. The peptide’s detectable urinary metabolites allow anti‑doping laboratories to screen for illicit GH‑releasing hormone use. Preliminary gene‑therapy data suggest that chronic elevation of GHRH may favorably modify lipid profiles and blood pressure, though evidence is limited to a single case.

Limitations of the Evidence

The compound has been withdrawn from the market and lacks regulatory approval for therapeutic use. Human data are confined to small, often single‑center studies; the Parkinson disease challenge showed no differential GH response, and the gene‑therapy findings come from a solitary N‑of‑1 experiment. Sex‑specific variability in biomarker response limits its utility for doping detection in women. No large‑scale safety or efficacy trials have been published, and the peptide’s broader pituitary effects remain incompletely characterized.

Safety Considerations

Published studies report no serious acute adverse events following single‑dose somatorelin injections, and hematological parameters were unchanged in a short‑term biomarker trial. In the long‑term gene‑therapy case, the subject experienced some adverse events but no overt acromegaly or marked IGF‑I elevation. In vitro adenoma experiments showed that somatorelin can stimulate multiple pituitary hormones, suggesting potential for off‑target endocrine effects in susceptible tissues. Overall, safety data are sparse and derived from limited cohorts.

How It Is Administered

Somatorelin is administered by injection, typically intravenously or subcutaneously, in research or diagnostic settings. The peptide is supplied as a sterile solution for parenteral use. In gene‑therapy applications, a plasmid encoding the GHRH sequence is delivered intramuscularly, leading to endogenous peptide production.

Routes of Administration

Goals & Uses

• Short stature treatmentPediatric EndocrinologyModerate
• Stimulation of endogenous GH secretionEndocrineModerate
• Treatment of growth hormone deficiency in childrenEndocrine/GrowthModerate
• Diagnosis of GH deficiencyDiagnosticHigh

Contraindications

• Hypothalamic GHRH-secreting tumorOncologicHigh
• Active intracranial neoplasmOncologicHigh
• Hypersensitivity to somatorelin or excipientsAllergy/ImmunologicHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• Antibody FormationImmunologicalUncommon
• Hypersensitivity/allergic reactionImmunologicalRare
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• InsulinLowMay increase risk of low blood sugar
• GlucocorticoidsModerate
• Thyroid hormonesModerate
• Somatostatin analogs (e.g., octreotide)High

Population Constraints

• PregnancyReproductive SafetyRelative
• Neonates/InfantsPediatricRelative
• ObesityMetabolicRelative

Regulatory Status

• European UnionWithdrawnNo longer actively marketed in the EU.
• United StatesWithdrawnApproved: Diagnostic evaluation of pituitary GH secretory capacity, Long-term treatment of GH deficiency in children (subcutaneous)Geref was approved by the FDA and later voluntarily withdrawn from the US market by the manufacturer.

Geref (somatorelin) was approved by the FDA but subsequently withdrawn from the US market. It was used for diagnostic testing of GH deficiency and for short stature indications in children.

Evidence & Sources

• Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy
  Journal ArticleModerateFriess E, et al.2001-01-01T00:00:00.000000Z
• Native Chemical Ligation-Photodesulfurization in Flow
  Journal ArticleLowChisholm TS, et al.2018-01-01T00:00:00.000000Z
• The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters
  Journal ArticleLowEricsson M, et al.2020-01-01T00:00:00.000000Z
• Results of a 5-Year N-of-1 Growth Hormone Releasing Hormone Gene Therapy Experiment
  Journal ArticleLowHanley BP, Brewer K, Church G2021-01-01T00:00:00.000000Z
• Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin
  Journal ArticleLowFelix I, et al.1994-01-01T00:00:00.000000Z
• Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples
  Journal ArticleLowCristea CD, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions